Live Breaking News & Updates on Recombinant Fibroblast Growth Factor 21 Analog

Stay updated with breaking news from Recombinant fibroblast growth factor 21 analog. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Pegozafermin associated with improved outcomes in nonalcoholic steatohepatitis

1. In this randomized controlled trial, treatment with pegozafermin improved fibrosis in patients with nonalcoholic steatohepatitis (NASH). 2. Treatment with pegozafermin led to increased rates of NASH resolution. Evidence Rating Level: 1 (Excellent) Study Rundown: NASH is a disease characterized by hepatic inflammation and excess fat accumulation with or without fibrosis of the liver. Pegozafermin ....

Minute Medicine Inc , Rating Level , Controlled Trial , Confidence Interval , Chronic Disease , Nonalcoholic Steatohepatitis Outcomes , Recombinant Fibroblast Growth Factor 21 Analog ,